Carver Biosciences is developing CRISPR-Cas13-based antiviral therapies that target and degrade the RNA of respiratory viruses, including influenza A and SARS-CoV-2. This platform technology addresses the lack of broad-spectrum antiviral treatments, enabling rapid response to viral outbreaks and pandemics.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antiviral treatments often have a narrow spectrum of activity, and developing new therapeutics can take many years, leaving a gap in our ability to respond effectively to viral outbreaks and pandemics caused by RNA viruses. Broad-spectrum antiviral therapies are lacking.
Solution
Carver Biosciences is developing a CRISPR-based platform technology that targets and degrades the RNA of respiratory viruses, including influenza A and SARS-CoV-2. The core of the technology, named CARVER, uses Cas13 to directly target and degrade viral RNA. This approach offers a programmable and potentially generalizable solution for treating multiple viruses, as targeting is dictated by a guide RNA sequence. The company leverages expertise in oligonucleotide therapeutics to enhance the effectiveness of its CRISPR-based antiviral platform.
Target Audience
The primary target audience includes individuals at risk from respiratory viral infections, as well as public health organizations and governments seeking rapid response solutions for viral outbreaks and pandemics.
Features
- CRISPR-Cas13-based technology for targeted degradation of viral RNA
- Programmable platform adaptable to various RNA viruses through guide RNA sequences
- Focus on respiratory viruses, including influenza A, RSV, and SARS-CoV-2